CLLAN webinar – How are advances in Bruton’s tyrosine kinase targeted therapies continuing to change how chronic lymphocytic leukemia (CLL) is treated? – video recording
On 7 December 2022, CLLAN (CLL Advocates Network) hosted a webinar – “How are advances in Bruton’s tyrosine kinase targeted therapies continuing to change how chronic lymphocytic leukemia (CLL) is treated?”.
The webinar aimed to explain in an understandable way the basic science behind BTK targeted therapies in use or study today to treat CLL. What different descriptions mean, how treatments work, how they are used and latest developments.
During this session we explored:
- What is Bruton’s tyrosine kinase (BTK) and why is it an important treatment target in CLL?
- 1st and 2nd generation Bruton’s tyrosine kinase inhibitors (BTKi), how different are they?
- How have side effect profiles and outcomes changed with BTKi advances?
- Non-covalent BTKi, how do they differ from existing BTKi in use today?
- What does covalent, non-covalent and reversible mean?
- Emerging technologies, such as BTK degraders, what are they and how do they work?
- How are BTK targeted therapies continuing to change the chronic lymphocytic leukemia (CLL) treatment landscape?
We were joined by:
Pierre Aumont – CLL Patient, Vice Chair, CLL Advocates Network, Trustee, Ensemble Leucemie Lymphomes Espoir, (ELLyE) (France)
Prof Chris Pepper – RM Phillips Chair in Experimental Medicine, Brighton and Sussex Medical School, University of Sussex, England (UK)
Prof Chris Fegan – retired Consultant Haematologist, Emeritus Professor, School of Medicine, Cardiff University, Wales (UK)
Jan Rynne – CLL Patient, Trustee, CLL Ireland (CLLI) (Ireland)
A big thank you to our panellists for their excellent presentation, insight and for sharing their wealth of experience.
This webinar was organised by CLL Advocates Network.
We would like to thank the following for their support: